Shufen Cai

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Lawrence M. Gelbert, Shufen Cai, Xi Lin et al. · Investigational New Drugs · 2014 · 565 citations · Full text

Medicine, Oncology, Pharmacology +17

Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts

Sonya C. Tate, Shufen Cai, Rose T. Ajamie et al. · Clinical Cancer Research · 2014 · 127 citations · Full text

Medicine, Oncology, Pharmacology +16

ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

Shripad V. Bhagwat, William T. McMillen, Shufen Cai et al. · Molecular Cancer Therapeutics · 2019 · 108 citations · Full text

Medicine, Oncology, Pharmacology +17

Effects of Thiol-Modifying Agents on a K(Ca 2+ ) Channel of Intermediate Conductance in Bovine Aortic Endothelial Cells

Shufen Cai, Rémy Sauvé · The Journal of Membrane Biology · 1997 · 67 citations

Natural Sciences, Biochemistry, Biophysics +17

Single-Channel Characterization of the Pharmacological Properties of the K(Ca 2+ ) Channel of Intermediate Conductance in Bovine Aortic Endothelial Cells

Shufen Cai, Line Garneau, Rémy Sauvé · The Journal of Membrane Biology · 1998 · 48 citations

Natural Sciences, Pharmacology, Physiology +17